Overview:

Summary

Global Markets Direct’s, 'Thrombocythaemia Myelofibrosis - Pipeline Review, Q2 2011', provides an overview of the Thrombocythaemia Myelofibrosis therapeutic pipeline. This report provides information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis. 'Thrombocythaemia Myelofibrosis - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Thrombocythaemia Myelofibrosis.
- A review of the Thrombocythaemia Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Thrombocythaemia Myelofibrosis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Thrombocythaemia Myelofibrosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Thrombocythaemia Myelofibrosis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Thrombocythaemia Myelofibrosis 8
Thrombocythaemia Myelofibrosis Therapeutics under Development by Companies 10
Thrombocythaemia Myelofibrosis Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Thrombocythaemia Myelofibrosis Therapeutics - Products under Development by Companies 14
Thrombocythaemia Myelofibrosis Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Thrombocythaemia Myelofibrosis Therapeutics Development 16
AstraZeneca PLC 16
YM BioSciences Inc. 16
Novartis AG 17
Incyte Corporation 17
S*BIO Pte Ltd 18
PharmaMar, S.A. 18
Thrombocythaemia Myelofibrosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
AZD1480 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
LBH589 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SB939 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CYT387 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
INCB18424 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Aplidin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Pomalidomide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CC-4047 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Thrombocythaemia Myelofibrosis Therapeutics – Drug Profile Updates 35
Thrombocythaemia Myelofibrosis - Featured News 39
Dec 08, 2010: Incyte Provides Positive Phase II Trial Results Of INCB18424 In Myeloproliferative Neoplasms 39
Oct 18, 2010: S*BIO's SB1518 Receives Orphan Drug Designation From European Commission For Treatment Of Myelofibrosis 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 42
Contact Us 42
Disclaimer 42"

List of Tables
Number of Products Under Development for Thrombocythaemia Myelofibrosis, Q2 2011 8
Products under Development for Thrombocythaemia Myelofibrosis – Comparative Analysis, Q2 2011 9
Number of Products under Development by Companies, Q2 2011 10
Number of Products under Investigation by Universities/Institutes, Q2 2011 11
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 12
Comparative Analysis by Early Clinical Stage Development, Q2 2011 13
Products under Development by Companies, Q2 2011 14
Products under Investigation by Universities/Institutes, Q2 2011 15
AstraZeneca PLC, 2011 16
YM BioSciences Inc., 2011 16
Novartis AG, 2011 17
Incyte Corporation, 2011 17
S*BIO Pte Ltd, 2011 18
PharmaMar, S.A., 2011 18
Assessment by Monotherapy Products, Q2 2011 19
Assessment by Stage and Route of Administration, Q2 2011 21
Assessment by Molecule Type, Q2 2011 23
Thrombocythaemia Myelofibrosis Therapeutics – Drug Profile Updates 35"

List of Figures
Number of Products under Development for Thrombocythaemia Myelofibrosis, Q2 2011 8
Products under Development for Thrombocythaemia Myelofibrosis – Comparative Analysis, Q2 2011 9
Products under Development by Companies, Q2 2011 10
Products under Investigation by  Universities/Institutes, Q2 2011 11
Mid Clinical Stage Products, Q2 2011 12
Early Clinical Stage Products, Q2 2011 13
Assessment by Monotherapy Products, Q2 2011 19
Assessment by Route of Administration, Q2 2011 20
Assessment by Stage and Route of Administration, Q2 2011 21
Assessment by Molecule Type, Q2 2011 22
Assessment by Stage and Molecule Type, Q2 2011 23